BRAF and melanoma: The discovery that ∼50% of human melanomas harbour activating V600E mutations in the serine/threonine kinase BRAF has raised the possibility that these tumours may be amenable to targeted therapy (Davies et al, 2002; Smalley and Flaherty, 2009).